ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI To Push “Cancer Prevention Awareness” This Month; Three RFPs Delayed For Changes

February 17, 1984

In Brief: Muggia Leaving NCI For NYU In September; Seminar Planned On radiation Exposures

April 20, 1979

Cooperative Groups: Group Affiliates, Statistical Offices At Top Of NCI’s Most Needy Cases List

November 13, 1998

NCI To Expand Funds for Cancer Centers, SPOREs, Director Tells House Appropriators

March 29, 2002

Working Group Beings AID-Related Lymphoma research

October 19, 1990

CDC Offers Funds For 5-A-Day Program; CDC PA Available

May 14, 1999